Cargando…
An antibiotic’s journey from marketing authorization to use, Norway
Here we describe in detail marketing authorization and reimbursement procedures for medicinal products in Norway, with particular reference to nine novel antibiotics that received marketing authorization between 2005 and 2015. The description illustrates that, in places like Norway, with effective a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Health Organization
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328106/ https://www.ncbi.nlm.nih.gov/pubmed/28250535 http://dx.doi.org/10.2471/BLT.16.172874 |
_version_ | 1782510856061321216 |
---|---|
author | Årdal, Christine Blix, Hege Salvesen Plahte, Jens Røttingen, John-Arne |
author_facet | Årdal, Christine Blix, Hege Salvesen Plahte, Jens Røttingen, John-Arne |
author_sort | Årdal, Christine |
collection | PubMed |
description | Here we describe in detail marketing authorization and reimbursement procedures for medicinal products in Norway, with particular reference to nine novel antibiotics that received marketing authorization between 2005 and 2015. The description illustrates that, in places like Norway, with effective antibiotic stewardship policies and an associated low prevalence of antibiotic-resistant bacterial infection, there is little need for newer, more expensive antibiotics whose therapeutic superiority to existing compounds has not been demonstrated. Since resistance begins to emerge as soon as an antibiotic is used, Norway’s practice of leaving newer antibiotics on the shelf is consistent with the goal of prolonging the effectiveness of newer antibiotics. An unintended consequence is that the country has signalled to the private sector that there is little commercial value in novel antibiotics, which may nevertheless still be needed to treat rare or emerging infections. Every country aims to improve infection control and to promote responsible antibiotic use. However, as progress is made, antibiotic-resistant bacteria should become less common and, consequently, the need for, and the commercial value of, novel antibiotics will probably be reduced. Nevertheless, antibiotic innovation continues to be essential. This dilemma will have to be resolved through the introduction of alternative reward systems for antibiotic innovation. The DRIVE-AB (Driving re-investment in research and development and responsible antibiotic use) research consortium in Europe has been tasked with identifying ways of meeting this challenge. |
format | Online Article Text |
id | pubmed-5328106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | World Health Organization |
record_format | MEDLINE/PubMed |
spelling | pubmed-53281062017-03-02 An antibiotic’s journey from marketing authorization to use, Norway Årdal, Christine Blix, Hege Salvesen Plahte, Jens Røttingen, John-Arne Bull World Health Organ Policy & Practice Here we describe in detail marketing authorization and reimbursement procedures for medicinal products in Norway, with particular reference to nine novel antibiotics that received marketing authorization between 2005 and 2015. The description illustrates that, in places like Norway, with effective antibiotic stewardship policies and an associated low prevalence of antibiotic-resistant bacterial infection, there is little need for newer, more expensive antibiotics whose therapeutic superiority to existing compounds has not been demonstrated. Since resistance begins to emerge as soon as an antibiotic is used, Norway’s practice of leaving newer antibiotics on the shelf is consistent with the goal of prolonging the effectiveness of newer antibiotics. An unintended consequence is that the country has signalled to the private sector that there is little commercial value in novel antibiotics, which may nevertheless still be needed to treat rare or emerging infections. Every country aims to improve infection control and to promote responsible antibiotic use. However, as progress is made, antibiotic-resistant bacteria should become less common and, consequently, the need for, and the commercial value of, novel antibiotics will probably be reduced. Nevertheless, antibiotic innovation continues to be essential. This dilemma will have to be resolved through the introduction of alternative reward systems for antibiotic innovation. The DRIVE-AB (Driving re-investment in research and development and responsible antibiotic use) research consortium in Europe has been tasked with identifying ways of meeting this challenge. World Health Organization 2017-03-01 2017-01-19 /pmc/articles/PMC5328106/ /pubmed/28250535 http://dx.doi.org/10.2471/BLT.16.172874 Text en (c) 2017 The authors; licensee World Health Organization. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL. |
spellingShingle | Policy & Practice Årdal, Christine Blix, Hege Salvesen Plahte, Jens Røttingen, John-Arne An antibiotic’s journey from marketing authorization to use, Norway |
title | An antibiotic’s journey from marketing authorization to use, Norway |
title_full | An antibiotic’s journey from marketing authorization to use, Norway |
title_fullStr | An antibiotic’s journey from marketing authorization to use, Norway |
title_full_unstemmed | An antibiotic’s journey from marketing authorization to use, Norway |
title_short | An antibiotic’s journey from marketing authorization to use, Norway |
title_sort | antibiotic’s journey from marketing authorization to use, norway |
topic | Policy & Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328106/ https://www.ncbi.nlm.nih.gov/pubmed/28250535 http://dx.doi.org/10.2471/BLT.16.172874 |
work_keys_str_mv | AT ardalchristine anantibioticsjourneyfrommarketingauthorizationtousenorway AT blixhegesalvesen anantibioticsjourneyfrommarketingauthorizationtousenorway AT plahtejens anantibioticsjourneyfrommarketingauthorizationtousenorway AT røttingenjohnarne anantibioticsjourneyfrommarketingauthorizationtousenorway AT ardalchristine antibioticsjourneyfrommarketingauthorizationtousenorway AT blixhegesalvesen antibioticsjourneyfrommarketingauthorizationtousenorway AT plahtejens antibioticsjourneyfrommarketingauthorizationtousenorway AT røttingenjohnarne antibioticsjourneyfrommarketingauthorizationtousenorway |